left-arrow right-arrow pinterest facebook google_plus linkedin

Gynecology Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


GOG-0238

Radiation Therapy With or Without Cisplatin in Treating Patients with Recurrent Endometrial Cancer

Status: Recruiting | Phase II

Official Title: A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus

Study Purpose: To determine if adding chemotherapy to radiation therapy is better than radiation therapy alone to treat patients with endometrial cancer that has come back. Learn more


GOG-0263

Radiation Therapy With or Without Chemotherapy In Patients with Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Status: Recruiting | Phase III

Official Title: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy.

Study Purpose: To determine if adding chemotherapy to radiation therapy (CRT) can prevent or lengthen the time to recurrence when compared to radiation therapy (RT) alone. Learn more.


GOG-0264

Status: Recruiting | Phase II

Official Title: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for newly diagnosed advanced stage and recurrent chemo naive Sex Cord-Stromal tumors of the ovary.

Study Purpose: The purpose of this study is to find out whether treatment with the drugs Paclitaxel and Carboplatin work better to control your cancer than treatment with the drugs Bleomycin, Etoposide and Cisplatin, which is the standard treatment for your type of cancer. Another purpose of this study is to find out what side effects are caused by treatment with these drug combinations and whether inhibin levels (a blood test) might be a good way to know how someone is responding to treatment. Learn more.


NRG GY005

Status: Recruiting | Phase III

Official Title: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Study Purpose: To confirm the effectiveness of the combination of Cediranib and Olaparib to the standard chemotherapy. Learn more


NRG GY007

Status: Recruiting | Phase II

Official Title: Testing the Addition of Ruxolitinib to Usual Chemotherapy Before and After Surgery in Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer-Phase II Portion

Study Purpose: To compare the effectiveness of the combination of Ruxolitinib with chemotherapy (Carboplatin and Paclitaxel) to the effectiveness of chemotherapy alone. Learn more


NRG GY009

Status: Recruiting | Phase III

Official Title: A Randomized, Phase II/III Study Of Pegylated Liposomal Doxorubicin And Ctep-Supplied Atezolizumab (Ind #134427) Versus Pegylated Liposomal Doxorubicin/Bevacizumab And Ctep-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab In Platinum Resistant Ovarian Cancer

Study Purpose: The purpose of this study is to compare any good and bad effects of adding Atezolizumab to the usual chemotherapy, (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab. Learn more.


NRG GY012

Status: Suspended | Phase II

Official Title: A Randomized, PhaseII Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.

Study Purpose: The purpose of this study is to compare the effects, good and bad, of using experimental study drugs: Cediranib alone, Olaparib alone, or a combination of Cediranib and Olaparib in recurrent endometrial cancer. This study will allow the researchers to know if one of these approaches is better, the same, or worse than the usual approach. Learn more


RTOG-0724

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy.

Status: Recruiting | Phase III 

Official Title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Study Purpose: To determine if adding chemotherapy after the usual treatment of chemotherapy and radiation therapy will prevent or lengthen the time to recurrence when compared to the usual treatment of chemotherapy and radiation therapy alone. Learn more.